Related Experiment Video

Updated: May 15, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Berberine represses DAXX gene transcription and induces cancer cell apoptosis

Jiansha Li1, Lubing Gu, Hailong Zhang

  • 1Institute of Pathology, Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Laboratory Investigation; a Journal of Technical Methods and Pathology
|January 9, 2013
PubMed

Insights

Berberine (BBR) inhibits Death-domain-associated protein (DAXX) gene expression by binding to its promoter region. This downregulation of DAXX leads to cancer cell death via a p53-dependent pathway.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Death-domain-associated protein (DAXX) regulates cell survival and apoptosis.
  • The regulation of DAXX gene expression is not well understood.
  • Berberine (BBR), a natural product, has been shown to downregulate DAXX expression transcriptionally.

Purpose of the Study:

  • To elucidate the mechanisms by which BBR transcriptionally suppresses DAXX.
  • To investigate the role of Sp1 and Ets1 transcription factors in DAXX regulation.
  • To explore the downstream effects of BBR-induced DAXX downregulation in cancer cells.

Main Methods:

  • Promoter analysis and mapping to identify the core DAXX promoter region.
  • Electrophoretic mobility shift assays (EMSAs) or similar techniques to confirm transcription factor binding.
  • Experimental validation of BBR's effect on DAXX promoter activity and transcription factor association.
  • Analysis of downstream signaling pathways, including MDM2 and p53 activation.

Main Results:

  • The core DAXX promoter region (-161 to -1) contains Sp1 and Ets1 consensus sequences.
  • Sp1 and Ets1 bind to the DAXX promoter and stimulate its transcription.
  • BBR binds to the DAXX core promoter, suppressing its activity by disrupting Sp1/Ets1 binding.
  • BBR-induced DAXX downregulation inhibits MDM2, leading to p53 activation and cancer cell apoptosis.

Conclusions:

  • BBR inhibits DAXX transcription by competitively binding to Sp1 and Ets1 consensus sequences on the DAXX promoter.
  • This novel mechanism induces cancer cell apoptosis through a p53-dependent pathway.
  • BBR represents a potential therapeutic agent for cancer by targeting the DAXX-MDM2-p53 axis.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...